Nonalcoholic fatty liver disease
Showing 1 - 25 of >10,000
Non-Alcoholic Fatty Liver Disease Trial in Seoul (GODEX, Placebo)
Enrolling by invitation
- Non-Alcoholic Fatty Liver Disease
- GODEX
- Placebo
-
Seoul, Korea, Republic ofSeoul National University Hospital
Nov 30, 2023
NAFLD Trial in Cairo (Lubiprostone 24Mcg Oral Cap)
Recruiting
- NAFLD
- Lubiprostone 24Mcg Oral Cap
-
Cairo, EgyptNational Hepatology and Tropical Medicine Research Institute
Mar 2, 2023
Type 2 Diabetes, Non Alcholic Fatty Liver Disease Trial (Bempedoic acid)
Not yet recruiting
- Type 2 Diabetes
- Non Alcholic Fatty Liver Disease
- Bempedoic acid
- (no location specified)
Sep 14, 2023
Non-alcoholic Fatty Liver Disease Trial in Zagazig (Rybelsus Oral Product, Ozempic Injectable Product, Tocopherol and/or Actos)
Recruiting
- Non-alcoholic Fatty Liver Disease
- Rybelsus Oral Product
- +2 more
-
Zagazig, Sharkia, EgyptZagazig University
Apr 1, 2023
Heart Failure With Preserved Ejection Fraction, Non Alcoholic Fatty Liver Trial in Sohag (echocardiography)
Not yet recruiting
- Heart Failure With Preserved Ejection Fraction
- Non Alcoholic Fatty Liver
- echocardiography
-
Sohag, El Monshah, Egypt
- +1 more
Apr 7, 2023
Nonalcoholic Fatty Liver Disease Trial (Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver
Not yet recruiting
- Nonalcoholic Fatty Liver Disease
- Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
- (no location specified)
Aug 8, 2022
Nonalcoholic Steatohepatitis, Genetic Risk Factor Trial (ALN-PNP Dose Level 1, ALN-PNP Dose Level 2, ALN-PNP Dose Level 3)
Not yet recruiting
- Nonalcoholic Steatohepatitis
- Genetic Risk Factor
- ALN-PNP Dose Level 1
- +3 more
- (no location specified)
Sep 5, 2023
Observational Study About Patients Diagnosed With NAFLD
Recruiting
- Nonalcoholic Fatty Liver Disease
-
Changsha, Hunan, ChinaDepartment of Infectious Disease, Xiangya Hospital, Central Sout
Nov 25, 2022
Nonalcoholic Fatty Liver Disease Trial in Jerusalem (Anti-human CCL24 mAb (CM-101) - Part One, Anti-human CCL24 mAb (CM-101) -
Completed
- Nonalcoholic Fatty Liver Disease
- Anti-human CCL24 monoclonal antibody (CM-101) - Part One
- +3 more
-
Jerusalem, IsraelHadassah University Hospital - Ein Kerem
Sep 13, 2023
Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver
Not yet recruiting
- Nonalcoholic Fatty Liver Disease
- Endoscopic Sleeve Gastroplasty
-
Morgantown, West VirginiaWest Virginia University
Aug 16, 2022
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD Trial (Efinopegdutide, Semaglutide, Placebo)
Not yet recruiting
- Non-alcoholic Fatty Liver Disease
- +4 more
- Efinopegdutide
- +2 more
- (no location specified)
May 17, 2023
Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Enrolling by invitation
- Nonalcoholic Fatty Liver Disease
-
Nashville, TennesseeVanderbilt University Medical Center
Jul 5, 2022
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) Trial in Gainesville (Lanifibranor, Placebo)
Recruiting
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Type 2 Diabetes (T2DM)
- Lanifibranor
- Placebo
-
Gainesville, FloridaUniversity of Florida
Sep 20, 2022
Weight Gain After Smoking Cessation and NAFLD
Completed
- Nonalcoholic Fatty Liver Disease
- Type 2 Diabetes
-
Ningbo, Zhejiang, ChinaNingbo first hospital
Sep 20, 2022
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Trial in Damanhur (Dapagliflozin 10mg Tab, Placebo)
Recruiting
- Nonalcoholic Fatty Liver Disease
- Type 2 Diabetes
- Dapagliflozin 10mg Tab
- Placebo
-
Damanhūr, Elbehairah, EgyptRehab Hussein Werida
Aug 11, 2022
Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal Trial (Denosumab, Alendronate Sodium)
Not yet recruiting
- Nonalcoholic Fatty Liver
- Osteoporosis, Postmenopausal
- Denosumab
- Alendronate Sodium
- (no location specified)
Aug 6, 2022
Nonalcoholic Fatty Liver Disease in HIV Database
Recruiting
- NAFLD
- +2 more
-
Birmingham, Alabama
- +7 more
Jan 11, 2023
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD Trial in San Antonio (AZD7503 Intervention)
Active, not recruiting
- Non-alcoholic Fatty Liver Disease
- +5 more
- AZD7503 Intervention
-
San Antonio, TexasResearch Site
Jan 13, 2023
Type 2 Diabetes With Complication Trial in Xi'an (Canagliflozin, Pioglitazone)
Recruiting
- Type 2 Diabetes Mellitus With Complication
-
Xi'an, Shannxi, ChinaFirst Affiliated Hospital Xi'an Jiaotong University
Aug 22, 2022
Type 2 Diabetes With Complication Trial (Canagliflozin, Pioglitazone)
Not yet recruiting
- Type 2 Diabetes Mellitus With Complication
- (no location specified)
Jul 5, 2022
Hypercholesterolemia Trial (HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose)
Not yet recruiting
- Hypercholesterolemia
- HSK31679 low dose
- +4 more
- (no location specified)
Mar 20, 2023
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis Trial in Yokohama (Experimental: 4 mg/day of WY-8678 (guanabenz acetate),
Active, not recruiting
- Nonalcoholic Fatty Liver
- Nonalcoholic Steatohepatitis
- Experimental: 4 mg/day of WY-8678 (guanabenz acetate)
- Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
-
Yokohama, Kanagawa, JapanYokohama City University
Sep 25, 2022
Kuwait Adult Diabetes Epidemiological Multidisciplinary Program
Recruiting
- Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
- +2 more
-
Kuwait City, KuwaitDasman Diabetes Institute
Oct 30, 2023
PCOS, NAFLD, NASH Trial in San Francisco, Durham
Recruiting
- PCOS
- +2 more
-
San Francisco, California
- +1 more
Nov 3, 2023